

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1602
Policy Title	Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation
Lead Commissioner	Gabriel Lawson
Clinical Reference Group	Chemotherapy
Which stakeholders were contacted to be involved in policy development?	<p>A policy working group was established as per NHS England policy, clinical and PPV reps were members of the chemotherapy CRG.</p> <p>All CRG members and registered stakeholders were sent copies of the draft policy documents for comment. The Children and Young Adult Cancer Services CRG and the BMT CRG were also consulted.</p>
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	<p>All of the relevant Royal Colleges and professional societies have membership on the CRG. These include:</p> <ul style="list-style-type: none"> British Oncology Pharmacy Association Royal College of Pathologists British Society for Haematology <p>A representative for each group was sent all policy documents and given the opportunity to comment.</p>
Which stakeholders have actually been involved?	<p>CRG members and a response from both the NCRN AML WG and the Wessex Strategic Clinical Network Haematology Site Specific Group.</p> <p>The Children and Young Adult Cancer Services CRG and the BMT CRG both provided responses.</p>
Explain reason if there is any difference from previous question	N/A

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>N/A</p>
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>As per policy development process all CRG members and CRG registered stakeholders have been sent draft policy documents for comment.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Mention of outdated British Society for Haematology guidelines has been removed from the Policy Proposition.</p> <p>Stakeholders highlighted evidence from within the Evidence Review they felt should have been given more weight, however these were uncontrolled retrospective studies included by the reviewer as background. Stakeholders also expressed concerns with the weighting of outcome measures used to assess the effectiveness of this treatment, but regardless which of the outcome measures were given greatest weight the evidence was scarce. Stakeholders also expressed a desire for data from CDF usage to be included in the Policy Proposition, but this data has not been published and therefore cannot be included.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>Communication will be according to NHS England policy development process.</p>
<p>What level of wider public consultation is recommended by the CRG for</p>	<p>The CRG recommends 60 days public consultation based on the level of stakeholder response and the nature of the policy.</p>

the NPOC Board to agree as a result of stakeholder involvement?	
---	--

Draft for consultation